A Study of LY3314814 in Participants With Liver Impairment

NCT03499041 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Stopped for futility. Phase 3 studies not likely to meet primary endpoints.

Conditions

Hepatic Impairment

Interventions

DRUG: LY3314814

Sponsor

Eli Lilly and Company

Collaborators

[object Object]